anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions in Placebo-Controlled Trials with Dihydroergotamine (DHE) Mesylate Nasal Spray [see Clinical Studies (14)]

Of the 1,796 patients and subjects treated with DHE nasal spray doses 2 mg or less in U.S. and foreign clinical studies, 26 (1.4%) discontinued because of adverse events. The adverse events associated with discontinuation were, in decreasing order of frequency: rhinitis (13), dizziness (2), facial edema (2), and one patient each due to cold sweats, accidental trauma, depression, elective surgery, somnolence, allergy, vomiting, hypotension, and paraesthesia.

Table 1 summarizes the incidence rates of adverse reactions reported by at least 1% of patients who received DHE nasal spray for the treatment of migraine during placebo-controlled, double-blind clinical studies and were more frequent than in those patients receiving placebo. The most commonly reported adverse reactions (greater than 1% of patients who received DHE nasal spray) were rhinitis, nausea, altered sense of taste, application site reactions, dizziness, vomiting, somnolence, pharyngitis, and diarrhea. In most instances these events were transient and self-limited and did not result in patient discontinuation from a study.

Adverse Reactions in Studies with TRUDHESA

An open-label study in adults (18 to 66 years of age) was conducted to evaluate the safety and tolerability of TRUDHESA, repeated use of TRUDHESA was allowed over the course of 6 to 12 months. A total of 354 patients with migraine received at least one dose of TRUDHESA. One hundred and eighty-five patients treated on average at least two migraines per month for 6 months, and 55 patients treated on average at least two migraines per month for 12 months. Of the patients who received at least one dose of TRUDHESA, 185 (52.3%) patients experienced local irritative symptoms. Of these, the most common local irritative symptoms were nasopharyngitis, rhinitis, nasal discomfort, product taste abnormal/dysgeusia, sinusitis, sinus discomfort, olfactory test abnormal, epistaxis, pharyngitis, nasal mucosal disorder, change in smell, ear discomfort, and rhinorrhea [see Warnings and Precautions (5.9)].
Stroke is the main cause of disability in the middle and old age. Hemiplegia, especially lower limb paralysis, often leads to the loss of self-care ability and a series of secondary injuries. The main method to improve hemiplegic limb movement is exercise therapy, but there are still many patients with disabilities after rehabilitation treatment. As one of the non-pharmacological therapies for stroke, acupuncture has been recognized to improve motor function in patients. Here, we propose a new method, anterior sciatic nerve acupuncture, which can stimulate both the femoral nerve and the sciatic nerve. We designed this study to determine the effect of this method on lower limb motor function. Sixty participants recruited with hemiplegia after cerebral infarction will be randomly assigned to the test group or control group in a 1:1 ratio. The control group will receive Xingnao Kaiqiao acupuncture, and the test group will receive anterior sciatic nerve acupuncture on this basis. All participants will get acupuncture treatment once a day, 6 times a week for 2 weeks. The primary outcome is Fugl-Meyer Assessment of Lower Extremity and the secondary outcomes are Modified Ashworth Scale and Modified Barthel Index. Data will be collected before treatment, 1 week after treatment, and 2 weeks after treatment, and then statistical analysis will be performed. This study can preliminarily verify the effect of anterior sciatic nerve acupuncture on improving lower limb motor function in patients with cerebral infarction, which may provide an alternative approach for clinical treatment of hemiplegia.
FIELD: medicine, sorbents. SUBSTANCE: affine sorbent has a carrier containing an immobilized human α 2 --macroglobulin. Method of a sorbent preparing involves immobilization of human α 2 --macroglobulin at pH 7.0-8.2 followed by its treatment with thio-ester loop modifying agent. The latter is monomethylamine hydrochloride or proteolytic enzyme plasmin of human blood plasma. Invention can be used for development of new approaches to treatment of patients with sicknesses caused by massive inflow of cytokines in blood, for example, as a result of septic shock. EFFECT: improved method of sorbent preparing, enhanced effectiveness of sorbent. 4 cl, 4 ex
A method includes receiving, by a master infusion device from a server, at least one fluid delivery protocol. The fluid delivery protocol includes one or more parameters for delivering a fluid to a user. The method also includes configuring, by the master infusion device, a first slave infusion pump with a first fluid delivery protocol of the at least one fluid delivery protocol. The method further includes configuring, by the master infusion device, a second slave infusion pump with a second fluid delivery protocol of the at least one fluid delivery protocol. The method also includes delivering, by the first slave infusion pump and based on the first fluid delivery protocol, the fluid to the user. Related methods and articles of manufacture, including apparatuses and computer program products, are also disclosed.
BACKGROUND: Multisystem Inflammatory Syndrome in Children (MIS-C) associated with SARS-CoV-2 can lead to severe cardiovascular complications. Anakinra, an interleukin-1 receptor antagonist, is proposed to benefit the hyperinflammatory state of MIS-C, potentially improving cardiac function. This systematic review evaluated the effectiveness of early Anakinra administration on cardiac outcomes in children with MIS-C.
METHODS: A comprehensive search across PubMed, Embase, and Web of Science until March 2024 identified studies using Anakinra to treat MIS-C with reported cardiac outcomes. Observational cohorts and clinical trials were included, with data extraction focusing on cardiac function metrics and inflammatory markers. Study quality was assessed using the Newcastle-Ottawa Scale.
RESULTS: Six studies met the inclusion criteria, ranging from retrospective cohorts to prospective clinical studies, predominantly from the USA. Anakinra dosages ranged from 2.3 to 10 mg/kg based on disease severity. Several studies showed significant improvements in left ventricular ejection fraction and reductions in inflammatory markers like C-reactive protein, suggesting Anakinra's role in enhancing cardiac function and mitigating inflammation. However, findings on vasoactive support needs were mixed, and some studies did not report significant changes in acute cardiac support requirements.
CONCLUSION: Early Anakinra administration shows potential for improving cardiac function and reducing inflammation in children with MIS-C, particularly those with severe manifestations. However, the existing evidence is limited by the observational nature of most studies and lacks randomized controlled trials (RCTs). Further high-quality RCTs are necessary to conclusively determine Anakinra's effectiveness and optimize its use in MIS-C management for better long-term cardiac outcomes and standardized treatment protocols.
The invention relates to small RNAs targeting a tissue factor (TF) gene and a use thereof and especially relates to a use of the small RNAs in preparation of drugs for treating diseases related to choroid and retinal neovascularization. The diseases related to choroid and retinal neovascularization comprises age-related macular degeneration (AMD), diabetic retinopathy and the like caused by abnormal neovascularization. The selected small RNAs targeting a TF gene can inhibit abnormally-high expression of a TF gene in a pathological state and can reduce TF gene-caused cell apoptosis after being injected into a vitreous cavity so that AMD drying is prevented. The small RNAs targeting a TF gene can prevent choroid neovascularization (CNV) caused by a TF gene thereby preventing wet AMD generation. Through use of the small RNAs targeting a TF gene, side-effects caused by over and direct inhibition of a vascular endothelial growth factor (VEGF) can be avoided. The small RNAs targeting a TF gene can be used for treating diseases related to choroid and retinal neovascularization.
The invention discloses a preparation method and application of fermentation compound bacteria and a myrtle fermentation extract. The method comprises the steps of screening polyphenol-resistant strains, treating the raw materials of the myrtle leaves, compounding the myrtle fermentation strains, carrying out microbial fermentation and preparing the myrtle fermentation extract. The invention obtains the fermentation composite bacteria of the antibacterial substance-resistant polyphenol through the strain screening and compounding technology. The biological fermentation technology is applied to the field of extraction of active component polyphenol of myrtle, and the extraction rate can be obviously improved. The preparation method is mild in condition and easy to control, and not only can extract the active ingredients in the myrtle leaves to the maximum extent, but also can effectively avoid the active ingredients from being damaged. The obtained fermented extract of myrtle has positive effects on animal production performance, feed utilization and diarrhea prevention.
FIELD: veterinary medicine.SUBSTANCE: group of inventions relates to the field of veterinary medicine, veterinary microbiology and biotechnology and can be used for the specific prevention of infectious pathologies caused by bacteria of the species Mannheimia haemolytica, Bibersteinia trehalosi and Pasteurella multocida. Associated inactivated vaccine against mancheimiosis, biebersteinosis and pasteurellosis of cattle and small ruminants contains the following components per 1 cm3of the preparation: inactivated protective antigen of Mannheimia haemolytica strain No. 822-VIEV serotype A1 - 2 billion microbial cells; inactivated protective antigen of Mannheimia haemolytica strain No. 1050-VIEV serotype A2 - 2 billion microbial cells; inactivated protective antigen of the Bibersteinia trehalosi strain No. 984-VIEW - 2 billion microbial cells; inactivated protective antigen of the Pasteurella multocida strain No. 1042-VIEV type A - 2 billion microbial cells; inactivated protective antigen of the Pasteurella multocida strain No. 163-VIEV type B - 2 billion microbial cells as well as pharmaceutically acceptable target additives. The group of inventions also relates to a method for producing this vaccine.EFFECT: use of this group of inventions makes it possible to obtain multivalent inactivated vaccines based on a balanced antigenic composition containing the most common serotypes of bacteria of the species Mannheimia haemolytica, Bibersteinia trehalosi, Pasteurella multocida in the territory of the Russian Federation and providing the creation of long-term and intense immunity in vaccinated animals.7 cl, 9 tbl, 15 ex
The present invention relates to a composition for coating the skin wherein the composition forms a waterproof flexible film on the skin. Preferably, the flexible film is durable and is capable of remaining adhered to the skin for 1 to 3 days. The composition may include (i) one or more pigments and/or dyes, or (ii) one or more sunscreen agents or (iii) one or more therapeutic agents for preventing or treating disorders of the skin. The coating composition comprises resin and flexibilizer (platicizer). Any suitable type of natural or synthetic resin may be used, preferably the resin is shellac or other natural gum derivative. A suitable flexiblizer is an animal, vegetable, mineral or synthetic oil, preferably castor oil, pine oil, rosehip oil or soya bean oil or mixture thereof. The composition optionally includes a diluent such as ethanol, a cellulosic preparation such as ethyl cellulose, an anti-agglomerating or dispersing agent and a thickener. The composition may be in the form of a paste, cream, gel, liquid or aerosol and may be used as a bandage or artificial skin.
The present invention relates to a preparation method of an oral liquor for reducing enzyme, which belongs to the technical field of a preparation method of a Chinese medicinal preparation. The existing Chinese medicinal preparation for treating glutamic pyruvic transaminase increase caused by various hepatitides has the disadvantages of not ideal effect, long course of treatment, low effective rate of treatment and low cure rate. The preparation method has the technical scheme that the oral liquor is prepared from the raw materials of 15 to 25 parts of rhubarb, 15 to 20 parts of capillary wormwood herb, 15 parts of giant knotweed rhizome, 6 to 10 parts of northern vietnamese sophora root, 15 to 20 parts of red sage root, 15 parts of forsythia fruit, 25 to 30 parts of oldenlandia, 6 to 9 parts of gentian root, 15 to 20 parts of therapeutic schisandra fruit, 15 to 20 parts of isatis root, 15 to 20 parts of dandelion and 20 to 30 parts of stringy stonecrop herb according to parts by weight. The raw materials are pulverized, uniformly stirred, poured into a medicine pot and decocted for a period of time after boiling, and a first physic liquor is obtained by filtration; then, water is added again, the raw materials are decocted for a period of time, and a second physic liquor is obtained by filtration; the first physic liquor and the second physic liquor are mixed to prepare the oral liquor for reducing enzyme. The preparation method has the advantage of simple technology. The prepared oral liquor has the advantages of short course of treatment for patients with hepatitides, high effective rate and high cure rate.
The Treatment as Usual (TAU) arm shall be a telephonic regular contact: with a total of 5 reminder calls on days 10, 30, 45, 60 and 90 after baseline intervention. The session shall include a reminder for the next planned follow up session and a general query for overall wellbeing.
<P>PROBLEM TO BE SOLVED: To provide an official examination system of prescription dosage receipt computer by which prescription/dosage mistakes are more conveniently prevented.  <P>SOLUTION: Suitable prescription dosage is set in a receipt computer by performing dosage check of prescription of the dosage by estimating standard weight of an applicable patient from the date of birth by a medical chart, etc. if the patient is at the prescription side and estimating the standard weight from the date of birth by prescription when the patient is at the prescription compliance side. When more than double of the prescription dosage of remedies is prescribed, since the suitable dosage or a warning sentence, etc. on a screen of each receipt computer, double doubt reference is performed by a pharmacist and the receipt computer, the suitable dosage of the remedy is re-examined to conveniently prevent the prescription/compounding mistakes.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Inflammatory bowel diseases (IBD) result from uncontrolled inflammation in the intestinal mucosa leading to damage and loss of function. Both innate and adaptive immunity contribute to the inflammation of IBD and innate and adaptive immune cells reciprocally activate each other in a forward feedback loop. In order to better understand innate immune contributions to IBD, we developed a model of spontaneous 100% penetrant, early onset colitis that occurs in the absence of adaptive immunity by crossing villin-TNFAIP3 mice to RAG1-/- mice (TRAG mice). This model is driven by microbes and features increased levels of innate lymphoid cells in the intestinal mucosa. To investigate the role of type 3 innate lymphoid cells (ILC3) in the innate colitis of TRAG mice, we crossed them to retinoid orphan receptor gamma t deficient (Rorγt-/-) mice. Rorγt-/- x TRAG mice exhibited markedly reduced eosinophilia in the colonic mucosa, but colitis persisted in these mice. Colitis in Rorγt-/- x TRAG mice was characterized by increased infiltration of the intestinal mucosa by neutrophils, inflammatory monocytes, macrophages and other innate cells. RNA and cellular profiles of Rorγt-/- x TRAG mice were consistent with a lack of ILC3 and ILC3 derived cytokines, reduced antimicrobial factors, increased activation oof epithelial repair processes and reduced activation of epithelial cell STAT3. The colitis in Rorγt-/- x TRAG mice was ameliorated by antibiotic treatment indicating that microbes contribute to the ILC3-independent colitis of these mice. Together, these gene expression and cell signaling signatures reflect the double-edged sword of ILC3 in the intestine, inducing both proinflammatory and antimicrobial protective responses. Thus, Rorγt promotes eosinophilia but Rorγt and Rorγt-dependent ILC3 are dispensable for the innate colitis in TRAG mice.
PURPOSE:To provide the titled preparation having excellent transintestinal absorbability and mitigated irritation and unagreeable feeling to the mouth and gastric mucosa in the administration of ionized calcium preparation, by adding reduced maltose and/or citric acid to ionized calcium of electrolyzed oyster shell. CONSTITUTION:The ionized calcium of electrolyzed oyster shell is a Ca preparation produced from electrolyzed oyster shell obtained by the electrolytic purification of oyster shell, and has remarkably high transintestinal absorbability compared with conventional Ca preparation. However, it has strong alkalinity and is liable to cause stimulation and nausea when administered in a empty stomach. It has been found that the disagreeable feeling of the ionized calcium of electrolyzed oyster shell can be mitigated without lowering the transintestinal absorbability of the ionized calcium by adjusting the pH of the preparation with reduced maltose and/or citric acid. The amounts of the reduced maltose and citric acid are preferably 0.3-3pts. and 1-2pts. per 1pt. of the ionized calcium of electrolyzed oyster shell.
Although clinical examination still represents the gold standard for the differential diagnosis of prolonged disorders of consciousness (pDoC), the introduction of innovative markers is essential for diagnosis and prognosis, due to the problem of covert cognition. We evaluated the brain-derived neurotrophic factor protein (BDNF) and the soluble cell adhesion molecules proteins (CAMs) in a cohort of prolonged disorders of consciousness patients to identify a possible application in the clinical context. Furthermore, peripheral blood determinations were correlated with imaging parameters such as white matter hyperintensities (WMH), cranial standardized uptake value (cSUV), electroencephalography (EEG) data and clinical setting. Our results, although preliminary, identify BDNF as a possible blood marker for the diagnosis of pDoC (p value 0.001), the soluble CAMs proteins CD44, Vcam-1, E-selectin (p value < 0.01) and Icam-3 (p value < 0.05) showed a higher peripheral blood value in pDoC compared with control. Finally, soluble Ncam protein could find useful applications in the clinical evolution of the pDoC, showing high levels in the MCS and EMCS subgroups (p value < 0. 001) compared to VS/UWS.
Polysomnography is the gold-standard for obstructive sleep apnea (OSA) diagnosis. However, OSA is still undiagnosed. Maxillofacial profile can influence OSA severity. Morphological characteristics can be identified but are not enough measurable and analysable by physicians. 3D acquisition of maxillofacial characteristics with a user-friendly tool, quick and low-priced could be used to obtain a predictive model as an OSA risk indicator. Thus, the aim of this study is to establish and evaluate a predictive model to diagnose OSA with maxillofacial characteristics 3D acquisition.
We will enroll 40 adult obese individuals. Each participant will take the assigned dose of medication once in the morning and a placebo pill in the evening for 28 days. We evaluate Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure at baseline and after 28 days of intervention.
Breast Cancer Survivor Group includes: women between the ages of 18 to 69 who have received a stage I-III diagnosis of breast cancer in the past and completed primary treatment and finished with treatment for at least 6 months; currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
The invention relates to the field of toilet requisites, and concretely relates to a strawberry and watermelon mouthwash. The mouthwash comprises, by weight, 15-20 parts of strawberries, 15-20 parts of a watermelon, 5-8 parts of propolis, 3-5 parts of tea polyphenols, 3-5 parts of Sarcandra glabra (Thunb.) Nakai, 5-8 parts of Tween, 5-8 parts of cyanine glycosides, 5-8 parts of honeysuckle flowers, 5-8 parts of licorice root and 45-55 parts of purified water. The mouthwash adopts strawberries, the watermelon and the Sarcandra glabra (Thunb.) Nakai as main raw materials, wherein the strawberries contain tooth bleaching and cleaning components and have tea stain and coffee stain cleaning effects on the oral cavity and teeth after eating, the watermelon contains rich vitamin c, the vitamin C protects teeth and gums, has an anti-oxidation effect and prevents tooth ageing, and the Sarcandra glabra (Thunb.) Nakai can clean the teeth, is tasty, and has antibiosis, anti-inflammation, bad breath removal, spirit raising and brain refreshing effects. The mouthwash has the advantages of tasty taste, obvious effects, safety and no toxicity, and is suitable for various populations to use.
The invention belongs to the technical field of biological medicine, and relates to a sequence structure of a novel antibody and application thereof. The antibody comprises: a first single domain antibody, wherein the amino acid sequence of the first single domain antibody comprises HCDR1, HCDR2 and HCDR3 shown in SEQ ID NO. 1-3; and/or; an amino acid sequence having at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO. 1-3; a second single domain antibody, the amino acid sequence of which comprises HCDR4, HCDR5 and HCDR6 with the sequence shown in SEQ ID NO 4-6; and/or; an amino acid sequence having at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO. 4-6. The tandem single domain antibody has higher affinity, good stability and better blocking effect, and has important significance in clinical treatment of autoimmune diseases and cancers.
This group will receive a Stage-Tailored Manual at baseline. It will also get Stage Tailored Feedback Reports based on assessments at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
The invention discloses a mobile health quarantine data analysis system. The system consists of a data acquisition terminal, a data storage and processing center and a data display and application terminal, which are connected through a wireless network. The data acquisition terminal is mobile equipment and is used for acquiring various health quarantine data; the data storage and processing center is based on the cloud platform, stores, processes and analyzes quarantine data, generates a statistical report and the like; the data display and application terminal is also mobile equipment and is used for intuitively displaying the processed data and providing interactive feedback. The system can adjust the data processing mode according to different scenes, thereby realizing intelligent quarantine information management and greatly improving the working efficiency and quality. The system adopts means such as encryption, authentication and the like to ensure the data security. The system improves the epidemic quarantine level and is beneficial to public health guarantee.